[{"address1": "The Mediaworks", "address2": "191 Wood Lane White City", "city": "London", "zip": "W12 7FP", "country": "United Kingdom", "phone": "44 20 3829 6230", "website": "https://www.autolus.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 463, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christian Martin Itin Ph.D.", "age": 59, "title": "CEO & Director", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 2399947, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Martin  Pule M.D., MBBS", "age": 51, "title": "Founder, Senior VP & Chief Scientific Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert F. Dolski", "age": 52, "title": "Senior VP & CFO", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Vann", "age": 58, "title": "Senior VP & COO", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Brochu", "age": 67, "title": "Senior VP & Chief Technical Officer", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Swan", "age": 58, "title": "Senior VP & Chief Human Resources Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brent  Rice", "age": 57, "title": "Senior VP, Chief Commercial Officer & Site Head of US", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Olivia  Manser", "title": "Director of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alex  Driggs", "title": "Senior VP of Legal Affairs & General Counsel and Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Chris  Williams", "age": 43, "title": "Senior VP & Chief Business Development Officer", "yearBorn": 1980, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.11, "open": 4.11, "dayLow": 4.09, "dayHigh": 4.275, "regularMarketPreviousClose": 4.11, "regularMarketOpen": 4.11, "regularMarketDayLow": 4.09, "regularMarketDayHigh": 4.275, "beta": 2.029, "forwardPE": -7.067797, "volume": 886334, "regularMarketVolume": 886334, "averageVolume": 1675011, "averageVolume10days": 2950700, "averageDailyVolume10Day": 2950700, "bid": 4.15, "ask": 4.18, "bidSize": 1800, "askSize": 900, "marketCap": 1108911488, "fiftyTwoWeekLow": 1.79, "fiftyTwoWeekHigh": 7.45, "priceToSalesTrailing12Months": 653.0692, "fiftyDayAverage": 5.2095, "twoHundredDayAverage": 4.470975, "currency": "USD", "enterpriseValue": 1093212672, "floatShares": 91175493, "sharesOutstanding": 265926000, "sharesShort": 4069436, "sharesShortPriorMonth": 3152405, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0153, "heldPercentInsiders": 0.18037, "heldPercentInstitutions": 0.58544, "shortRatio": 3.99, "shortPercentOfFloat": 0.0207, "impliedSharesOutstanding": 265926000, "bookValue": 0.64, "priceToBook": 6.5156255, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -208383008, "trailingEps": -1.2, "forwardEps": -0.59, "enterpriseToRevenue": 643.824, "enterpriseToEbitda": -6.47, "52WeekChange": 1.0341463, "SandP52WeekChange": 0.26430142, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "AUTL", "underlyingSymbol": "AUTL", "shortName": "Autolus Therapeutics plc", "longName": "Autolus Therapeutics plc", "firstTradeDateEpochUtc": 1529674200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "da5466ad-c9a9-3bae-a4e5-c7afee3582d0", "messageBoardId": "finmb_562879769", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.17, "targetHighPrice": 16.0, "targetLowPrice": 6.9, "targetMeanPrice": 10.69, "targetMedianPrice": 11.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 239566000, "totalCashPerShare": 0.901, "ebitda": -168963008, "totalDebt": 223866000, "quickRatio": 5.904, "currentRatio": 6.154, "totalRevenue": 1698000, "debtToEquity": 200.824, "revenuePerShare": 0.01, "returnOnAssets": -0.25346002, "returnOnEquity": -1.01614, "freeCashflow": -125133872, "operatingCashflow": -145587008, "revenueGrowth": -1.0, "operatingMargins": -103.37338, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-10"}]